Fox Run Management’s Sarepta Therapeutics SRPT Stock Holding History

Fox Run Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,706	Closed	-$474K	–	1221
2025 Q2	$474K	Buy	+27,706	New	+$1.18M	0.08%	486
2024 Q2	–	Sell	-6,801	Closed	-$880K	–	1063
2024 Q1	$880K	Sell	6,801 -2,732	-29%	-$335K	0.19%	169
2023 Q4	$919K	Buy	+9,533	New	+$914K	0.23%	108
2022 Q3	–	Sell	-7,626	Closed	-$572K	–	814
2022 Q2	$572K	Buy	7,626 +341	+5%	+$25.1K	0.29%	96
2022 Q1	$569K	Buy	+7,285	New	+$558K	0.32%	69
2021 Q2	–	Sell	-4,902	Closed	-$365K	–	436
2021 Q1	$365K	Buy	+4,902	New	+$452K	0.66%	36
2019 Q2	–	Sell	-1,986	Closed	-$237K	–	614
2019 Q1	$237K	Buy	+1,986	New	+$255K	0.13%	347
2018 Q4	–	Sell	-3,117	Closed	-$503K	–	707
2018 Q3	$503K	Buy	+3,117	New	+$426K	0.22%	171
2017 Q4	–	Sell	-4,500	Closed	-$204K	–	876
2017 Q3	$204K	Buy	+4,500	New	+$180K	0.06%	604
2017 Q2	–	Sell	-13,100	Closed	-$388K	–	820
2017 Q1	$388K	Buy	+13,100	New	+$405K	0.16%	269

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fox Run Management's SRPT Position: Q3 2025 in Review

Fox Run Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 27,706 shares — an estimated $474K sold.

Fox Run Management first reported a position in SRPT in Q1 2017 and held it in 10 quarters. The position peaked at $919K in Q4 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Fox Run Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Fox Run Management sold 27,706 Sarepta Therapeutics shares in Q3 2025, an estimated $474K.
Fox Run Management first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 10 quarters.
Fox Run Management's Sarepta Therapeutics position peaked at $919K in Q4 2023.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.